Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Trial Details

NCT ID
NCT07517198
Phase
PHASE1
Sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • EXS74539
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Fort Worth, Texas, United States|32.72541,-97.32085
  • West Valley City, Utah, United States|40.69161,-112.00105

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Histologically confirmed diagnosis of the following solid tumors:
  • High grade neuroendocrine or small cell carcinomas of non-lung origin
  • Non-small cell lung cancer \[NSCLC\]

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →